Pfizers Q4, FY09 sees uptick
Pfizer has reported positive financial results for the fourth quarter and full year of 2009, recording only a slight uptick for Lipitor.
For fourth-quarter 2009, the New York City-based company reported net income of $767 million, an increase of 188 percent compared with $266 million in the prior-year quarter. For the full year of 2009, Pfizer reported net income of $8.6 billion, an increase of 7 percent compared with $8.1 billion last year.
Fourth-quarter 2009 revenues were $16.5 billion, an increase of 34 percent compared with $12.3 billion in the year-ago quarter. For fourth-quarter 2009, U.S. revenues were $7.4 billion, an increase of 42 percent compared with the year-ago quarter. International revenues were $9.1 billion, increasing by 28 percent compared with the prior-year quarter, and reflected 21 percent operational growth. U.S. revenues represented 45 percent compared with 42 percent of the total in the year-ago quarter, while international revenues represented 55 percent compared with 58 percent of the total in fourth-quarter 2008.
For 2009 fiscal year, revenues were $50 billion, an increase of 4 percent compared with $48.3 billion in the same period in 2008, according to the company. For full-year 2009, revenues were favorably impacted by approximately $3.3 billion, or 7 percent, due to the addition of the Wyeth products. U.S. revenues were $21.7 billion, increasing by 7 percent compared with full-year 2008. International revenues were $28.3 billion, increasing by 1 percent compared with last year. U.S. revenues represented 43 percent compared with 42 percent of the total last year, and international revenues represented 57 percent compared with 58 percent of the total in 2008.
The company also reported that revenues for its cholesterol-lowering blockbuster drug Lipitor rose in 2009 by 1 percent with $3.18 billion in 2009, compared with $3.15 billion in 2008. Also, the pulmonary arterial hypertension drug Revatio posted $131 million in 2009, compared with $95 million in 2008--representing a 38 percent increase.
For fourth-quarter 2009, the New York City-based company reported net income of $767 million, an increase of 188 percent compared with $266 million in the prior-year quarter. For the full year of 2009, Pfizer reported net income of $8.6 billion, an increase of 7 percent compared with $8.1 billion last year.
Fourth-quarter 2009 revenues were $16.5 billion, an increase of 34 percent compared with $12.3 billion in the year-ago quarter. For fourth-quarter 2009, U.S. revenues were $7.4 billion, an increase of 42 percent compared with the year-ago quarter. International revenues were $9.1 billion, increasing by 28 percent compared with the prior-year quarter, and reflected 21 percent operational growth. U.S. revenues represented 45 percent compared with 42 percent of the total in the year-ago quarter, while international revenues represented 55 percent compared with 58 percent of the total in fourth-quarter 2008.
For 2009 fiscal year, revenues were $50 billion, an increase of 4 percent compared with $48.3 billion in the same period in 2008, according to the company. For full-year 2009, revenues were favorably impacted by approximately $3.3 billion, or 7 percent, due to the addition of the Wyeth products. U.S. revenues were $21.7 billion, increasing by 7 percent compared with full-year 2008. International revenues were $28.3 billion, increasing by 1 percent compared with last year. U.S. revenues represented 43 percent compared with 42 percent of the total last year, and international revenues represented 57 percent compared with 58 percent of the total in 2008.
The company also reported that revenues for its cholesterol-lowering blockbuster drug Lipitor rose in 2009 by 1 percent with $3.18 billion in 2009, compared with $3.15 billion in 2008. Also, the pulmonary arterial hypertension drug Revatio posted $131 million in 2009, compared with $95 million in 2008--representing a 38 percent increase.